Niki BioSolutions, Inc. (NIKI)

Market Cap	11.75M -21.3%
Revenue (ttm)	n/a
Net Income	-2.25M
EPS	-2.86
Shares Out	2.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,481
Open	4.120
Previous Close	4.320
Day's Range	4.000 - 4.380
52-Week Range	0.600 - 12.240
Beta	-1.00
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 20, 2026

About NIKI

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 1
• Stock Exchange: Nasdaq
• Ticker Symbol: NIKI
• Website: https://www.aptorumgroup.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error